NCT03624023View on ClinicalTrials.gov

TWB-103 for Treating Lower Limb Ulcers on Patients With DM

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 19, 2019

Primary Completion Date

July 9, 2021

Study Completion Date

July 9, 2021

Conditions
Diabetic Foot Ulcer
Interventions
DRUG

TWB-103

TWB-103 will be applied to the target ulcer wound once a week by the investigator, starting from Day 1, until wound closure is confirmed or up to 12 weekly applications

Trial Locations (2)

114

Tri-Service General Hospital, Taipei

10048

National Taiwan University Hospital, Taipei

All Listed Sponsors
lead

Transwell Biotech Co., Ltd.

INDUSTRY

NCT03624023 - TWB-103 for Treating Lower Limb Ulcers on Patients With DM | Biotech Hunter | Biotech Hunter